On 09 March 2020, UroGen Pharma Ltd. (NASDAQ: URGN) changed -9.40% to recent value of $14.27. The stock transacted 343914 shares during most recent day however it has an average volume of 179.31K shares. It spotted trading -65.37% off 52-week high price. On the other end, the stock has been noted 0.42% away from the low price over the last 52-weeks.

UroGen Pharma Ltd. (URGN) recently reported financial results for the fourth quarter and full year ended December 31, 2019 and provided an overview of the Company’s recent developments.

Fourth Quarter and Full Year 2019 Financial Results; 2020 Guidance

As of December 31, 2019, cash, cash equivalents and marketable securities totaled $195.6M, not including restricted cash.

Research and development expenses for the three months ended December 31, 2019 were $20.1M, including non-cash share-based compensation expense of $1.9M. Research and development expenses for the year ended December 31, 2019 were $49.3M, including non-cash share-based compensation expense of $8.3M. The research and development expenses for the three months and year ended December 31, 2019 included an in-process research and development charge of $10.0M associated with the execution of the Agenus licensing contract.

General and administrative expenses for the three months ended December 31, 2019 were $19.7M, including non-cash share-based compensation expense of $6.2M. General and administrative expenses for the year ended December 31, 2019 were $60.2M, including non-cash share-based compensation expense of $21.7M.

UroGen stated a net loss of $39.0M, or basic and diluted net loss per ordinary share of $1.86, for the three months ended December 31, 2019. The Company stated a net loss of $105.1M, or basic and diluted net loss per ordinary share of $5.12, for the year ended December 31, 2019.

The Company anticipates operating expenses in the range of $145 to $155M for 2020. Non-cash stock-based compensation expense for 2020 is predictable to be in the range of $32 to $36M subject to market conditions, and other non-operating income for 2020 is anticipated to be about $2.5M.

UroGen has 21.0M ordinary shares outstanding.

The company has 27.3M of outstanding shares and 18.52M shares were floated in the market. According to the most recent quarter its current ratio was 7.6 that represents company’s ability to meet its current financial obligations. The price moved ahead of -45.36% from the mean of 20 days, -50.60% from mean of 50 days SMA and performed -52.82% from mean of 200 days price. Company’s performance for the week was -40.19%, -52.27% for month and YTD performance remained -57.24%.

LEAVE A REPLY

Please enter your comment!
Please enter your name here